A phase 2 biomarker study evaluating subjects with unresected, advanced melanoma treated with talimogene laherparepvec

Update Il y a 5 ans
Reference: EUCTR2013-005552-15

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To explore the correlation between a baseline immunoprofile (ie, intratumoral CD8+ cell density) and objective response rate (ORR) in subjects with unresected stage IIIB to IVM1c melanoma treated with talimogene laherparepvec.


Inclusion criteria

  • Unresected Stage IIIB to IVM1c Melanoma